Transaction · 0001193125-26-354313

Bizily Scott

Bizily Scott, CLO, reported an open-market or private sale at 4D Molecular Therapeutics, Inc. involving 1635.000000 shares for an estimated $19620.00. Reported holdings after the transaction were 8617.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCLO
FDMT4D Molecular Therapeutics, Inc.
Filing timeAug 17
Trade dateAug 13, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$14.54
Pre-filing
1mo ago -19.5%1w ago -27.4%1d ago -18.4%
Returns since
7d +5.8%30d -1.3%90d -1.3%180d -1.3%1y -1.3%

FDMT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
FDMT since 2026-08-17Filed 18 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-354313
Common Stock
Transaction date
Aug 13, 2026
Filed Aug 17, 2026, 09:34 PM · 4d delay
Shares
1.63k sh
$1.20k per share
Estimated value
-$1.96M
Computed from shares × price
Holdings after
8.61k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Legal Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.

  2. F2

    The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), suc…

Original filing · 0001193125-26-354313
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

FDMT